NCT01027260

Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

A Randomized, Placebo Controlled Study on the Efficacy of Itopride HCI on Irritable Bowel in Patients of Irritable Bowel Syndrome With Constipation (IBS-C)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 268 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms

Conditions

• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Itopride HCI 50 mg	Variable dosing
DRUG	Itopride HCI 100 mg	Variable dosing
DRUG	Placebo	Variable dosing

Timeline

• Start date: 2008-06-01
• Primary completion: 2010-08-01
• Completion: 2010-09-01
• First posted: 2009-12-07
• Last updated: 2013-06-18

Locations

4 sites across 1 country: Pakistan